Perrigo Company plc (PRGO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 29, 2024. Perrigo is a leading provider of over-the-counter (OTC) health and wellness solutions, operating primarily in North America and Europe. The company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The former Rx segment was divested in 2021 and is reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Sales | $1,065.5 million | $1,193.1 million | $2,147.5 million | $2,374.8 million |
| Gross Profit | $394.7 million | $428.0 million | $752.4 million | $841.9 million |
| Gross Margin | 37.0% | 35.9% | 35.0% | 35.5% |
| Operating Income (Loss) | $(26.5) million | $56.8 million | $(81.7) million | $105.4 million |
| Net Income (Loss) | $(108.4) million | $8.4 million | $(106.4) million | $5.4 million |
| Diluted EPS | $(0.79) | $0.06 | $(0.78) | $0.04 |
| Cash from Operations (YTD) | $8.1 million | $72.3 million | $8.1 million | $72.3 million |
| Total Debt (Outstanding) | $4,057.6 million | $4,073.4 million | $4,057.6 million | $4,073.4 million |
| Cash & Equivalents | $542.8 million | $751.3 million | $542.8 million | $751.3 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 10.7% in Q2 and 9.6% YTD. The decline was driven primarily by a 48.8% drop in U.S. Nutrition sales (infant formula) due to plant remediation and FDA compliance actions, alongside lower demand in Upper Respiratory and Pain & Sleep-Aids categories.
- Operating Loss: The company reported an operating loss of $26.5 million in Q2 compared to income of $56.8 million in the prior year. This shift was caused by a $34.1 million impairment charge related to the sale of the HRA Pharma Rare Diseases Business and increased restructuring costs.
- Restructuring Charges: Restructuring expenses totaled $36.9 million in Q2 (up from $6.7 million in Q2 2023), primarily associated with "Project Energize," a global efficiency program.
- Impairment Charges: A one-time impairment charge of $34.1 million was recorded in Q2, including $22.1 million in goodwill impairment, as the company classified the Rare Diseases Business as held for sale.
- Segment Performance:
- CSCA: Sales down 15.5% due to infant formula disruptions; operating income down 29.1%.
- CSCI: Sales down 2.5% (organic growth offset by currency headwinds); operating loss of $10.3 million driven by impairment charges.
Guidance, Outlook, and Risks
- Strategic Initiatives: "Project Energize" is expected to deliver annualized pre-tax savings of $140 million to $170 million by 2026. The "Supply Chain Reinvention Program" aims for $200 million to $300 million in annual run-rate savings by 2028.
- Infant Formula: The company has completed large-scale manufacturing resets at its U.S. infant formula sites. While production has resumed, results in 2024 are expected to be below 2023 levels due to unabsorbed overhead and remediation costs estimated at $15 million to $20 million for the year.
- Divestiture: The sale of the HRA Pharma Rare Diseases Business to Esteve Healthcare was completed on July 10, 2024. The gain/loss on de-recognition is expected to be minimal.
- Legal & Tax Risks:
- Securities Litigation: A proposed settlement of $97 million for a class action regarding 2015-2017 events received preliminary court approval; a final hearing is scheduled for September 2024. An additional $34 million provision was recorded in Q1.
- Antitrust: The DOJ advised in July 2024 that Perrigo is no longer a subject or target of its grand jury investigation into generic drug pricing.
- Tax: The company faces ongoing IRS audits regarding transfer pricing and ANDA-related issues. A partial valuation allowance was established in the U.S., projecting an unusually high effective tax rate for the full year 2024.
- Credit Ratings: S&P and Fitch downgraded the company's credit ratings in Q1 2024 (S&P to BB-, Fitch to BB), resulting in a step-up in interest rates on certain notes.
Investor Verification Checklist
- Infant Formula Recovery: Verify the timeline for full normalization of U.S. infant formula sales volumes and the extent of ongoing remediation costs beyond the estimated $15-20 million.
- Restructuring Execution: Monitor the progress of "Project Energize" and "Supply Chain Reinvention" to ensure projected savings materialize against the backdrop of reduced sales volumes.
- Legal Settlements: Confirm the final court approval of the $97 million securities litigation settlement and assess potential exposure from remaining opt-out cases and price-fixing lawsuits.
- Tax Liability: Review the resolution of the IRS transfer pricing disputes and the impact of the new valuation allowance on future effective tax rates.
- Debt Covenants: Ensure continued compliance with financial covenants (leverage and interest coverage ratios) given the recent credit rating downgrades and operating losses.